Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- MONDO_0004985 label "Bipolar disorder" assertion.
- MONDO_0004985 label "Bipolar disorder" assertion.
- MONDO_0004985 label "Bipolar disorder" assertion.
- MONDO_0004985 label "Bipolar depression" assertion.
- MONDO_0004985 label "bipolar disorder" assertion.
- MONDO_0004985 label "bipolar disorder" assertion.
- cohort label "Adults" assertion.
- association label "Only a few medications are available for the treatment of alcohol use disorders (AUDs). It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants." assertion.
- cohort label "Adults" assertion.
- association label "Only a few medications are available for the treatment of alcohol use disorders (AUDs). Areas covered: This paper discusses approved AUD medications, including the opioid antagonists naltrexone and nalmefene (the latter is licensed for reduction of alcohol consumption only), the putative glutamate receptor antagonist acamprosate and the aldehyde dehydrogenase inhibitor disulfiram. It also covers off-label medications of interest, including topiramate, gabapentin, ondansetron, varenicline, baclofen, sodium oxybate and antidepressants." assertion.
- step label "Put here a name of your awesome step (include the word awesome so others will find it)" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- image label "image" assertion.
- association label "Psychostimulants were associated with statistically significant improvement in depressive symptoms in major depressive disorder (odds ratio [OR], 1.41; 95% confidence interval [CI], 1.13-1.78; P = 0.003) and bipolar disorder (OR, 1.42; 95% CI, 1.13-1.78; P = 0.003). Efficacy outcomes differed across the psychostimulants evaluated as a function of response rates: ar/modafinil (OR, 1.47; 95% CI, 1.20-1.81; P = 0.0002); dextroamphetamine (OR, 7.11; 95% CI, 1.09-46.44; P = 0.04); lisdexamfetamine dimesylate (OR, 1.21; 95% CI, 0.94-1.56; P = ns); methylphenidate (OR, 1.49; 95% CI, 0.88-2.54; P = ns). Efficacy outcomes also differed between agents used as adjunctive therapy (OR, 1.39; 95% CI, 1.19-1.64) or monotherapy (OR, 2.25; 95% CI, 0.67-7.52)." assertion.
- cohort label "Adults" assertion.
- cohort label "Adults" assertion.
- association label "Psychostimulants were associated with statistically significant improvement in depressive symptoms in major depressive disorder (odds ratio [OR], 1.41; 95% confidence interval [CI], 1.13-1.78; P = 0.003) and bipolar disorder (OR, 1.42; 95% CI, 1.13-1.78; P = 0.003). Efficacy outcomes differed across the psychostimulants evaluated as a function of response rates: ar/modafinil (OR, 1.47; 95% CI, 1.20-1.81; P = 0.0002); dextroamphetamine (OR, 7.11; 95% CI, 1.09-46.44; P = 0.04); lisdexamfetamine dimesylate (OR, 1.21; 95% CI, 0.94-1.56; P = ns); methylphenidate (OR, 1.49; 95% CI, 0.88-2.54; P = ns)." assertion.
- association label "There is a substantial body of literature comprising anecdotal material and descriptions of uncontrolled and randomized controlled trials addressing the use of subanesthetic doses of ketamine for the off-label treatment of major depressive episodes." assertion.
- cohort label "Adults" assertion.
- cohort label "Elderly" assertion.
- association label "Prescriptions for five oral SGAs (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) were reviewed, and veterans were considered to be users if they received a minimum of one 30-day outpatient prescription for any dose or 3 consecutive days of inpatient administration (continuation at discharge was not required) in the 6 months after the index date." assertion.
- cohort label "Elderly" assertion.
- association label "Prescriptions for five oral SGAs (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) were reviewed, and veterans were considered to be users if they received a minimum of one 30-day outpatient prescription for any dose or 3 consecutive days of inpatient administration (continuation at discharge was not required) in the 6 months after the index date." assertion.
- cohort label "Elderly" assertion.
- association label "Prescriptions for five oral SGAs (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone) were reviewed, and veterans were considered to be users if they received a minimum of one 30-day outpatient prescription for any dose or 3 consecutive days of inpatient administration (continuation at discharge was not required) in the 6 months after the index date." assertion.
- cohortAgeMin label "describe the minimum age of the cohort (e.g. 7)" assertion.
- cohortAgeLabel label "describe the life stage or age of the cohort (e.g. Adults)" assertion.
- publication label "add the URL of a publication supporting this association (doi, PubMed...)" assertion.
- association label "this association" assertion.
- object label "search for the disease it treats" assertion.
- hasPhenotype label "provide additional phenotypes for the cohort" assertion.
- subject label "search for the indicated drug" assertion.
- cohort label "the study cohort" assertion.
- associationRelation label "provide the type of drug indication" assertion.
- readableassertion label "describe the assertion concisely (e.g. tylenol treats pain in adults patients)" assertion.
- cohortAgeMax label "describe the maximum age of the cohort (e.g. 80)" assertion.
- assertion label "Defining a drug indication with its context (BioLink model)" assertion.
- out1 label "out1" assertion.
- step label "heyhey" assertion.
- LinguisticSystem label "python" assertion.
- image label "image" assertion.
- cohort label "Adults" assertion.
- association label "Amitriptyline also has different off-label uses, including migraine prevention, neuropathic pain management, fibromyalgia, and enuresis (bedwetting)." assertion.
- MONDO_0005546 label "fibromyalgia" assertion.
- MONDO_0005546 label "fibromyalgia" assertion.
- MONDO_0005546 label "fibromyalgia" assertion.
- MONDO_0005546 label "Fibromyalgia" assertion.
- MONDO_0005546 label "Fibromyalgia" assertion.
- MONDO_0005546 label "Fibromyalgia" assertion.
- MONDO_0005546 label "Fibromyalgia" assertion.
- MONDO_0005546 label "Fibromyalgia" assertion.
- MONDO_0005546 label "Fibromyalgia" assertion.
- MONDO_0005546 label "Fibromyalgia" assertion.
- MONDO_0005546 label "Fibromyalgia" assertion.
- cohort label "Elderly" assertion.
- association label "Nonpharmacological interventions are suggested as first-line treatment, but aren't effective for every patient, resulting in pharmacological interventions for some patients, consisting of off-label use of antipsychotics, sedative/hypnotics, anxiolytics, acetylcholinesterase inhibitors, memantine, and antidepressants; where efficacy doesn't necessarily outweigh associated risks." assertion.
- MONDO_0004975 label "Alzheimer disease" assertion.
- MONDO_0004975 label "Alzheimer disease" assertion.
- MONDO_0004975 label "alzheimer disease" assertion.
- association label "Off-label use • Imipramine • Bupropion • Modafinil" assertion.
- cohort label "Adults" assertion.
- association label "Off-label use • Imipramine • Bupropion • Modafinil" assertion.
- cohort label "Adults" assertion.
- cohort label "Adults" assertion.
- association label "Haloperidol can also be used to treat behavioral disorders and hyperactivity, and it is sometimes used off-label for nausea and vomiting (from chemotherapy, advanced or terminal illness, and surgery), chorea (jerky, involuntary movements) associated with Huntington disease, treatment and prevention of delirium in the intensive care unit, obsessive- compulsive disorder (OCD), phencyclidine-induced psychosis, psychosis/agitation associated with dementia, and rapid control of agitation, aggression, and violent behavior" assertion.
- HP_0002072 label "Chorea" assertion.
- HP_0002072 label "Chorea" assertion.
- HP_0002072 label "Chorea" assertion.
- HP_0002072 label "Chorea" assertion.
- HP_0002072 label "Chorea" assertion.
- HP_0002072 label "Chorea" assertion.
- HP_0002072 label "Chorea" assertion.
- HP_0002072 label "Chorea" assertion.
- HP_0002072 label "Chorea" assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- MONDO_0011918 label "anxiety" assertion.
- MONDO_0011918 label "anxiety" assertion.
- MONDO_0011918 label "anxiety" assertion.
- MONDO_0011918 label "anxiety" assertion.
- MONDO_0011918 label "anxiety" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.